Brief: GeNeuro Announces Results From CHANGE-MS and ANGEL-MS Studies
15/07/2021 07:28
July 15 (Reuters) - Geneuro SA GNRO.PA :
* GENEURO ANNOUNCES THE PUBLICATION OF RESULTS FROM
CHANGE-MS AND
ANGEL-MS STUDIES
* DATA SHOWED PROMISING ANTI-NEURODEGENERATIVE EFFECT AND
SUPPORTS
CONTINUED DEVELOPMENT OF TEMELIMAB AGAINST DISABILITY
PROGRESSION IN MS
* ONGOING PHASE 2 STUDY AT KAROLINSKA INSTITUTET/ACADEMIC
SPECIALIST CENTER OF STOCKHOLM, SWEDEN, WITH RESULTS EXPECTED Q1
2022
Source text for Eikon: ID:nBw7Gk7tDa
Further company coverage: GNRO.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Geneuro SA
See all newsBrief: Geneuro SA Postpones Publication Of Half-Yearly Financial Report
Brief: Geneuro SA Announces Extension Of Its Definitive Debt-Restructuring Moratorium
Brief: Geneuro SA Announces The Opening Of Receivership Proceedings For Its French Subsidiary Geneuro Innovation Sas
Brief: Geneuro Confirms Top-Line Results In Its Post-Covid Trial By End-June
Brief: Geneuro announces EUR 5 Mln private placement